[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352206-105":59,"doc-detail-352206-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","egfr-dependent-delivery-of-phosphorylated-igfbp3-by-cancer-stem-cells-drives-chemotherapy-resistance-in-colorectal-cancer","EGFR-dependent delivery of phosphorylated IGFBP3 by cancer stem cells drives chemotherapy resistance in colorectal cancer","","Chemotherapy remains the primary systemic treatment for advanced colorectal cancer, yet drug resistance severely limits efficacy. Cancer stem cells are implicated in resistance, but the mechanism linking CSCs to broad tumor-cell refractoriness is unclear. This study shows colorectal CSC-like spheroid cells release small extracellular vesicles enriched with highly phosphorylated IGFBP3. Cell-free or endogenous IGFBP3 can directly trigger tumor apoptosis, whereas IGFBP3 from quiescent CCSCs promotes resistance via an EGFR-dependent pathway. VRK2 phosphorylates IGFBP3 at S201, enabling binding to EGFR and sorting into sEVs, which jointly suppress chemotherapy-induced DNA damage. VRK2 siRNA or D4476 reduces IGFBP3 phosphorylation and sEV incorporation, reversing resistance, supporting EGFR/sEV-targeted therapeutic strategies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/egfr-dependent-delivery-of-phosphorylated-igfbp3-by-cancer-stem-cells-drives-chemotherapy-resistance-in-colorectal-cancer/352206/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/egfr-dependent-delivery-of-phosphorylated-igfbp3-by-cancer-stem-cells-drives-chemotherapy-resistance-in-colorectal-cancer/352206.png","ImageObject",300,407,{"name":92,"@type":93},"MrHarris58","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main treatment challenge addressed in this study?","Question",{"text":112,"@type":113},"Advanced colorectal cancer is primarily treated with chemotherapy, but inevitable drug resistance leads to poor prognosis and reduced treatment effectiveness.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How do cancer stem cell-like spheroid cells promote chemotherapy resistance?",{"text":117,"@type":113},"They release small extracellular vesicles enriched with highly phosphorylated IGFBP3, which acts through an EGFR-dependent pathway in the tumor microenvironment.",{"name":119,"@type":110,"acceptedAnswer":120},"What mechanism links VRK2, IGFBP3 phosphorylation, and EGFR in sEVs?",{"text":121,"@type":113},"VRK2 is enriched in the CSC-like cells and phosphorylates IGFBP3 at the S201 site; phosphorylated IGFBP3 binds EGFR, enabling sorting into sEVs and co-delivery to recipient tumor cells.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},352206,1790131876,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},687212988360,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","[www.nature.com/cddis](www.nature.com/cddis)  \nARTICLE OPEN   \nEGFR-dependent delivery of phosphorylated IGFBP3 by cancer stem cells drives chemotherapy resistance in colorectal cancer  \nXinyu Gao1,7, Lian Zhang2,7, Haibo Wang1,7, Weiguo Zhang 1, Xiuhong Lu1, Jingyi Wang3,4, Liu Liu 4, You Zhang5, Xinshuang Wang1, Mengting Song6, Wei Xie1, Beibei Liang 1, Xiewei Kang 1, Jiaxin Zhang1, Gang Huang 1 ✉ and Hao Yang 1 ✉  \n© The Author(s) 2026  \n\n|  | The primary systemic treatment for advanced colorectal cancer (CRC) is chemotherapy, but inevitable drug resistance leads to poor prognosis. Cancer stem cells (CSCs) are recognized as signiﬁcant contributors to chemotherapy resistance, yet the mechanisms underlying their ability to induce widespread resistance across tumor cell populations remain poorly understood. In this study, we demonstrate a novel mechanism by which colorectal CSC-like spheroid cells (CCSCs) drive chemotherapy resistance through the release of small extracellular vesicles (sEVs) enriched with highly phosphorylated insulin-like growth factor binding protein-3 (IGFBP3) into the tumor microenvironment (TME) . While cell-free IGFBP3 or endogenous IGFBP3 directly induces apoptosis in tumor cells, IGFBP3 originating from quiescent CCSCs functions through an epidermal growth factor receptor (EGFR)-dependent pathway to promote chemotherapy resistance. Mechanistically, the protein kinase VRK2, which is highly enriched in CCSCs, leads to the phosphorylation of IGFBP3 at the S201 site. This phosphorylation enables IGFBP3 to bind to EGFR, facilitating its sorting and subsequent recruitment into sEVs. Both EGFR and phosphorylated IGFBP3 are co-delivered via sEVs to recipient tumor cells, where they inhibit chemotherapy-induced DNA damage and promote resistance. Importantly, siRNA targeting VRK2 or the inhibitor D4476 signiﬁcantly reduced IGFBP3 phosphorylation and its incorporation into sEVs, thereby reversing chemotherapy resistance. These ﬁndings highlight the dual role of IGFBP3 in CRC and provide critical insights into the core mechanism by which CCSCs drive chemotherapy resistance through EGFR and sEVs-mediated signaling, offering a novel therapeutic approach for personalized |  |\n| --- | --- | --- |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| treatment of CRC. |  |  |\n|  | Cell Death and Disease (2026)17:804; [https://doi.org/10.1038/s41419-026-09009-0](https://doi.org/10.1038/s41419-026-09009-0) |  |\n|  |  |  |\n\nINTRODUCTION  \nAccording to the latest GLOBOCAN 2022 data, colorectal cancer (CRC) ranks as the third most commonly diagnosed cancer globally and is the second leading cause of cancer-related mortality [1] . Although chemotherapy has been the cornerstone of CRC treatment for decades, metastatic progression and disease recurrence remain the primary contributors to mortality in advanced stages, with acquired resistance further compromising treatment efﬁcacy and patient survival [2] . Previous studies have highlighted the potential role of cancer stem cells (CSCs) as the key drivers behind tumor metastasis, recurrence, and therapeutic resistance [3, 4] .  \nCSC-like cells constitute a distinct subpopulation within tumors, characterized by a slow cell cycle, tumor-initiating potential, and self-renewal capacity [5, 6]. The tumor-initiating ability of CSC-like cells refers to their capacity to initiate new tumor formation at metastatic sites or to overcome microenvironmental challenges. Self-renewal, a deﬁning feature of CSC-like cells, provides long-term  \nproliferative potential, thereby driving cancer progression, metastasis, and resistance to therapy [7] . Current evidence suggests that tumor stemness represents a plastic cellular state, wherein nonCSCs can acquire stem cell-like properties, thereby contributing to tumor progression and therapeutic resistance [8] . Additionally, CSClike cells exhibit a quiescent s","cbCaicLFyQeeBNhK","https://ap.wps.com/l/cbCaicLFyQeeBNhK","pdf",9110422,17,"English","# Introduction\n## Cancer stem cells in chemotherapy resistance\n## Small extracellular vesicles (sEVs)\n## Study rationale and overview","[{\"question\":\"What is the main treatment challenge addressed in this study?\",\"answer\":\"Advanced colorectal cancer is primarily treated with chemotherapy, but inevitable drug resistance leads to poor prognosis and reduced treatment effectiveness.\"},{\"question\":\"How do cancer stem cell-like spheroid cells promote chemotherapy resistance?\",\"answer\":\"They release small extracellular vesicles enriched with highly phosphorylated IGFBP3, which acts through an EGFR-dependent pathway in the tumor microenvironment.\"},{\"question\":\"What mechanism links VRK2, IGFBP3 phosphorylation, and EGFR in sEVs?\",\"answer\":\"VRK2 is enriched in the CSC-like cells and phosphorylates IGFBP3 at the S201 site; phosphorylated IGFBP3 binds EGFR, enabling sorting into sEVs and co-delivery to recipient tumor cells.\"}]","EGFR-dependent delivery of phosphorylated IGFBP3 by cancer stem cells drives chemotherapy resistance in colorectal cancer | PDF",1790098298,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0f229008a573b9f95bbb718a4184830c.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4651890e591b3301a90dd4964ea96898.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bd41f6b9b9e0f0dc1af2133b5ba5074e.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dfecb0291731956a722a095e92b1d6b3.webp",980,1301]